Pharmaceutical sponsor
Shanghai Mabgeek Biotech.Co.Ltd Clinical Trials
Studies where Shanghai Mabgeek Biotech.Co.Ltd is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 9Chronic Rhinosinusitis With Nasal Polyps
A Study to Evaluate the Efficacy and Safety of MG-K10 in Adults With Chronic Rhinosinusitis With Nasal Polyps
This study aims to evaluate the efficacy and safety of MG-K10 humanized monoclonal antibody injection in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- NCT07903194
- Testing
- MG-K10, Mometasone Furoate Nasal Spray
- Volunteers
- 210 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Chronic Urticaria, Idiopathic
A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria
This Phase 2 study evaluates the efficacy and safety of MG-K10 in participants with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines.
- Trial name
- NCT07838727
- Testing
- MG-K10 Injection
- Volunteers
- 60 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Chronic Spontaneous Urticaria (CSU)
A Study of MG-K10 in Chronic Spontaneous Urticaria
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial aimed at evaluating the efficacy and safety of MG-K10 humanized monoclonal antibody injection in CSU trial participants with poor…
- Trial name
- NCT07546487
- Testing
- MG-K10 Humanized Monoclonal Antibody Injection
- Volunteers
- 226 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Dermatitis, Atopic
A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)
- Trial name
- NCT07540442
- Testing
- MG-K10 Injection (Humanized Monoclonal Antibody)
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Atopic Dermatitis, Atopic Eczema
A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis
Rationale (What is the reason for this study?) Atopic dermatitis (AD) is a condition that makes the skin dry and itchy and is the most common skin condition that causes redness and irritation.
- Trial name
- ADaggio (NCT07479615)
- Testing
- MG-K10 Humanized Monoclonal Antibody Injection
- Volunteers
- 498 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Prurigo Nodularis
Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis
A phase III clinical study to evaluate the efficacy and safety of a humanized MG-K10 mab injection in subjects with prurigo nodularis.administered every 4 weeks for 56 weeks.
- Trial name
- NCT06779136
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Seasonal Allergic Rhinitis
Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis
A multicenter, randomized, double-blind, placebo-controlled Phase II/III seamless clinical study evaluating the efficacy, safety, pharmacokinetic (PK) profile, pharmacodynamic (PD) profile, and immunogenicity of MG-K10 humanized…
- Trial name
- NCT06846385
- Testing
- MG-K10 Humanized Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Asthma
Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma
A randomized, double-blind, placebo-controlled Phase III clinical trial on the efficacy and safety of MG-K10 humanized monoclonal antibody injection in adolescent and adult patients with moderate to severe asthma.
- Trial name
- NCT06837922
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Atopic Dermatitis
IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients
This study was designed to reflect the safety pharmacokinetics and preliminary efficacy of MG-K10 Humanized Monoclonal Antibody Injection in adolescent patients 12-18 weeks of age with moderate to severe atopic dermatitis…
- Trial name
- NCT06765005
- Testing
- MG-K10
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd